PLUS THERAPEUTICS, INC.PSTVEarnings & Financial Report
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Houston, Texas, that develops targeted radiotherapeutics and diagnostic services for brain and central nervous system (CNS) cancers. The company’s lead therapeutic candidate, marketed as REYOBIQ™, is an investigational liposomal radiopharmaceutical under clinical evaluation for recurrent glioblastoma, leptomeningeal metastases, and certain pediatric brain cancers. Plus Therapeutics also commercialized a molecu...
PSTV Q3 2025 Key Financial Metrics
Revenue
$1.4M
Gross Profit
N/A
Operating Profit
$-4.5M
Net Profit
$-4.4M
Gross Margin
N/A
Operating Margin
-320.8%
Net Margin
-316.6%
YoY Growth
-4.1%
EPS
$-0.04
Financial Flow
PLUS THERAPEUTICS, INC. Q3 2025 Financial Summary
PLUS THERAPEUTICS, INC. reported revenue of $1.4M for Q3 2025, with a net profit of $-4.4M (-316.6% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $1.4M |
|---|---|
| Net Profit | $-4.4M |
| Gross Margin | N/A |
| Operating Margin | -320.8% |
| Report Period | Q3 2025 |
PLUS THERAPEUTICS, INC. Annual Revenue by Year
PLUS THERAPEUTICS, INC. annual revenue history includes year-by-year totals (for example, 2024 revenue was $5.8M).
| Year | Annual Revenue |
|---|---|
| 2024 | $5.8M |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $1.3M | $1.5M | $1.4M | $1.1M | $1.4M | $1.4M |
| YoY Growth | N/A | N/A | N/A | N/A | -36.9% | 8.7% | -4.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Assets | $5.6M | $11.2M | $7.0M | $6.6M | $12.1M | $10.3M | $18.7M |
| Liabilities | $10.5M | $18.8M | $12.2M | $15.6M | $35.7M | $7.3M | $13.6M |
| Equity | $-4.8M | $-7.6M | $-5.2M | $-8.9M | $-23.6M | $3.0M | $5.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-4.5M | $-1.1M | $-3.7M | $-1.2M | $-6.2M | $-5.8M | $-2.5M |
More Companies
AZN
ASTRAZENECA PLC
Revenue
$14.5B
Net Profit
$2.4B
NVS
NOVARTIS AG
NVO
NOVO NORDISK A S
SNY
Sanofi
GSK
GSK plc
TAK
TAKEDA PHARMACEUTICAL CO LTD
ARGX
ARGENX SE
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Revenue
$1.1B
Net Profit
$186.4M
ALC
ALCON INC
Revenue
$2.6B
Net Profit
$176.0M
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Revenue
$4.7B
Net Profit
$481.0M